Skip to main content


Showing posts from January, 2012

Low-molecular-weight heparin beats unfractionated in STEMI

A new meta-analysis has found that low-molecular-weight heparins (LMWHs) are associated with a reduction in mortality and major bleeding rates in STEMI patients treated with primary PCI as compared with unfractionated heparin (UFH) [ 1 ]. And patients at greatest risk seem to derive the most benefit from LMWHs, report   Dr Eliano Pio Navarese   (Nicolaus Copernicus University, Bydgoszcz, Poland) and colleagues in their paper published online July 20, 2011 in the   Journal of Thrombosis and Haemostasis .   UFH has generally been recognized as the standard anticoagulant for use in STEMI patients undergoing primary PCI, and current   AHA/ACC   and   European Society of Cardiology   (ESC) guidelines recommend the use of UFH in this setting, Navarese. And although preliminary data from the ATOLL study , which is not yet published, show the efficacy and safety of the LMWH   enoxaparin   for this use, ATOLL was underpowered to assess the effect of LMWHs on a single outcome such as morta